Menu
Our unique PEBL (Protein Expression BLocker) is one of the solutions we have specifically designed to overcome the major industry challenges faced by CAR T-cell therapy for T-cell malignancies.
We have a robust pipeline of research, focusing on leveraging an array of proprietary technologies that improve and expand T-cell function
Visionary scientist and creator of the first anti-CD19 CAR, Professor Dario Campana established MediSix Therapeutics in 2016 to help patients with complex and rare T-cell malignancies
Our unique PEBL (Protein Expression BLocker) is one of the solutions we have specifically designed to overcome the major industry challenges faced by CAR T-cell therapy for T-cell malignancies.
We have a robust pipeline of research, focusing on leveraging an array of proprietary technologies that improve and expand T-cell function
Visionary scientist and creator of the first anti-CD19 CAR, Professor Dario Campana established MediSix Therapeutics in 2016 to help patients with complex and rare, T-cell malignancies
Copyright MediSix Therapeutics 2022
Director of Discovery Sciences
Dr Lee is our Director of Discovery Sciences, where she evaluates and manages the transition of technologies or assets of interest into MediSix. She joined MediSix in 2018 and has more than 13 years of experience in immunology research.
Prior to joining Medisix, she was a Postdoctoral Research Fellow at the Singapore Immunology Network, where she studied the immunoprofile of solid tumors and the phenotype of tumor-associated macrophages. Yunqin holds a BEng in Biomedical Engineering from Imperial College London and her PhD in Immunology from Stanford University, where she studied immune evasion in cancer.
Assoc. Director of Development
Alicia joined MediSix as our Assoc. Director of Development, spearheading our Development team’s efforts to transition Discovery assets into clinical trials. She earned her B.Eng from Nanyang Technological University and worked as a Product Engineer for four years before making a daring career switch to Cell Therapy. She has since been a key contributor to developing manufacturing processes for Cell Therapy Products.
Before joining MediSix, Alicia was the Product Development Manager at Lion TCR. She specialised in crafting the production process for their TCR-T product had her work published in Hepatology and was integral to securing Phase 1B/2 FDA approval for their TCR-T product.
Board Member
Professor Poste has served on our Board of Directors since 2016. He is the Del E Webb Professor of Health Innovation and chief scientist with the Complex Adaptive Systems Initiative at Arizona State University (ASU). This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision medicine and the remote monitoring of health status using miniaturized body sensors and mobile devices. He assumed this post in 2009. From 2003 to 2009, he directed and built the Biodesign Institute at ASU.
He is a fellow of the UK Royal Society, the Royal College of Pathologists and the UK Academy of Medicine, a member of the Council for Foreign Relations, and US National Academy of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the US Department of Defense and currently serves on advisory committees for several US government agencies in defense, intelligence, national security and healthcare. George was recipient of the Scrip Lifetime Achievement Award in 2009 and named Scientist of the Year by R&D Magazine in 2004. George received his BSc, PhD and DVM at the University of Bristol, UK.
Board Member
Dr Harrington has served on our board since 2016. Bill has spent the last 20 years in venture capital and currently has been one of the managing partners at Osage University Partners (OUP) since 2011. Prior to this, he was General Partner at Three Arch Partners, a west coast venture capital firm with over $1 billion under management, where he focused on investing in life science companies including therapeutics, medical devices, and healthcare services. Bill was previously a practicing Interventional Radiologist in the San Francisco Bay Area.
Bill earned his BSc from Tufts University, summa cum laude, an MD from Harvard Medical School, and an MBA from the Haas Business School, University of California, Berkeley. Bill is a holder of the Chartered Financial Analyst designation. Bill is a member of the Board of Trustees at The Haverford School in Haverford, PA.
Board Member
Michael Carusi has served on our board of directors since 2016. He is an experienced venture capitalist focusing on investments in the biopharmaceutical and medical device sectors. He serves as a general partner for Lightstone Ventures based out of Palo Alto, CA where he is also a General Partner for Advanced Technology Ventures.
Featured on the Forbes Midas List of top technology investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare conferences. He serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, sits on the Tuck MBA Advisory Board, and is an advisory board member to the UCSF/Berkeley Venture Innovation Program.
Earlier in his career, Mike served as a Director of Business Development for Inhale Therapeutic Systems and was a Principal at The Wilkerson Group. Mike has a BSc in Mechanical Engineering from Lehigh University, and an MBA from the Tuck School of Business.
Vice President, Strategy and Intellectual Property
With over 15 years of experience in the biomedical industry, Dr Chuan is our Vice President of Strategy and Intellectual Property Development, overseeing MediSix’s collaborative research and development efforts, intellectual property strategy and assets. Prior to Medisix, Peiying held various portfolios at the Agency for Science, Technology and Research (A*STAR).
Most recently, she spearheaded the creation of a large scale, first-of-its-kind research programme in Singapore, and was pivotal in forging global strategic alliances with public and private organisations.
Her other portfolios included shaping of public research and development policies, research grant administration, and project management. Peiying holds a BSE in Bioengineering from the University of Pennsylvania, and a PhD in Biochemistry from Stanford University.
Director of Discovery Operations
Dr Tan is our Director of Discovery Operations, leading the Discovery team’s research efforts to advance MediSix’s pipeline. She joined MediSix in 2018 as a Research Scientist, and was a key driver in guiding the successful transition of our lead asset, PCART7, from discovery to development. Ying Xim has over 14 years of experience in immunology and cancer biology research.
She earned her BSc in Molecular and Cell Biology from the University of California, Berkeley and her PhD in Immunology from the University of California, San Francisco, where she studied the negative regulation of T cell receptor signaling. Prior to working with MediSix, Ying Xim was a Research Fellow at the Institute of Molecular and Cell Biology, studying the role of methytransferases in liver biology and cancer.
Vice President, Finance
Cecilia joined MediSix in May 2021 and is our Vice President, Finance. She has more than 18 years of corporate finance, fund raising, deal structuring, portfolio management and business advisory.
Prior to joining Medisix, she was the Head of Syndication at CapBridge, a fintech fund-raising platform. Cecilia holds a Master of Business Administration from the Wharton School of University of Pennsylvania, USA and a Bachelor of Accounting from Nanyang Technology University, Singapore. She is also a Chartered Financial Analyst.
Chief Executive Officer
As the CEO of MediSix Therapeutics based from our headquarters in Singapore, Andrew Bruce leads a strong and growing team in further developing the work of Professor Dario Campana in T-cell engineering. Andrew is an accomplished professional with more than 36 years in the pharmaceutical industry.
He has gained broad experience across a range of functions from sales and marketing to supply chain and logistics, medical affairs, therapy area strategy and corporate development. Andrew has held leadership positions within the pharmaceutical, biotech and medical consulting industries, in addition to commercial and strategy roles, including founding and subsequent sale of a global specialist medical consulting leader.
He moved to Singapore in March 2021. Andrew gained his BSc at the University of Bradford.
Scientific Founder
Professor Campana is the scientific founder of MediSix Therapeutics. An internationally renowned expert in cell therapy, he was the creator of the first anti-CD19-41BB-CD3z CAR that is the key component of Kymriah, the first CAR T-cell therapy approved by the FDA and marketed globally. Currently, Dario is Professor of Pediatrics at the National University of Singapore, and holds the Mrs Lee Kong Chian Chair in Advanced Cellular Therapy.
He is the recipient of consecutive Singapore Translational Research Investigator awards, the Jacob and Louise Gabbay Award in Biotechnology and Medicine and the Republic of Singapore President’s Technology Award. Dario is an elected member of the American Society for Clinical Investigation and the Association of American Physicians. In addition to MediSix, Dario is also the scientific founder of cell therapy start-ups Unum Therapeutics (Cambridge, MA) and Nkarta Therapeutics (San Francisco, CA) and holds several patents.
Dario obtained his MD and PhD in Italy at the University of Torino and the University of Milano, respectively. He trained as a scientist at the Royal Free Hospital, University of London, before moving to St. Jude Children’s Research Hospital in Memphis, where he was Full Member in the Departments of Oncology and Pathology, and Professor of Pediatrics at the University of Tennessee. Dario’s main interest is translational research in oncology, focusing on monitoring response to treatment in leukemia, and on immunotherapy of leukemia, lymphoma and solid tumors.